IL291175B2 - Compositions and methods for treating collagen-mediated diseases - Google Patents
Compositions and methods for treating collagen-mediated diseasesInfo
- Publication number
- IL291175B2 IL291175B2 IL291175A IL29117522A IL291175B2 IL 291175 B2 IL291175 B2 IL 291175B2 IL 291175 A IL291175 A IL 291175A IL 29117522 A IL29117522 A IL 29117522A IL 291175 B2 IL291175 B2 IL 291175B2
- Authority
- IL
- Israel
- Prior art keywords
- drug product
- less
- collagenase
- area
- sucrose
- Prior art date
Links
- 102000008186 Collagen Human genes 0.000 title claims 2
- 108010035532 Collagen Proteins 0.000 title claims 2
- 229920001436 collagen Polymers 0.000 title claims 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229940126534 drug product Drugs 0.000 claims 24
- 239000000825 pharmaceutical preparation Substances 0.000 claims 24
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 4
- 229930006000 Sucrose Natural products 0.000 claims 4
- 239000007983 Tris buffer Substances 0.000 claims 4
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 claims 4
- 239000005720 sucrose Substances 0.000 claims 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 4
- 108060005980 Collagenase Proteins 0.000 claims 3
- 102000029816 Collagenase Human genes 0.000 claims 3
- 229960002424 collagenase Drugs 0.000 claims 3
- 239000007972 injectable composition Substances 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims 2
- 102000013382 Gelatinases Human genes 0.000 claims 1
- 108010026132 Gelatinases Proteins 0.000 claims 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 claims 1
- 108010013295 Microbial collagenase Proteins 0.000 claims 1
- 240000003186 Stachytarpheta cayennensis Species 0.000 claims 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229960003767 alanine Drugs 0.000 claims 1
- 238000005571 anion exchange chromatography Methods 0.000 claims 1
- 108090001092 clostripain Proteins 0.000 claims 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 claims 1
- 108010052968 leupeptin Proteins 0.000 claims 1
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000004007 reversed phase HPLC Methods 0.000 claims 1
- 210000002435 tendon Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76347006P | 2006-01-30 | 2006-01-30 | |
| US78413506P | 2006-03-20 | 2006-03-20 | |
| US11/699,302 US7811560B2 (en) | 2006-01-30 | 2007-01-29 | Compositions and methods for treating collagen-mediated diseases |
| PCT/US2007/002654 WO2007089851A2 (en) | 2006-01-30 | 2007-01-30 | Compositions and methods for treating collagen-mediated diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL291175A IL291175A (en) | 2022-05-01 |
| IL291175B1 IL291175B1 (en) | 2023-10-01 |
| IL291175B2 true IL291175B2 (en) | 2024-02-01 |
Family
ID=38328033
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL291175A IL291175B2 (en) | 2006-01-30 | 2007-01-30 | Compositions and methods for treating collagen-mediated diseases |
| IL192878A IL192878A (en) | 2006-01-30 | 2008-07-17 | Clostridium histolyticum collagenase i and collagenase ii, drug comprising the same and process for producing said drug |
| IL245434A IL245434A (en) | 2006-01-30 | 2016-05-02 | Collagen-mediated Diseases and Methods for the Treatment of Collagen |
| IL254184A IL254184B (en) | 2006-01-30 | 2017-08-28 | Compositions and methods for treating collagen-mediated diseases |
| IL264361A IL264361B (en) | 2006-01-30 | 2019-01-21 | Compositions and methods for treating collagen-mediated diseases |
| IL277322A IL277322B (en) | 2006-01-30 | 2020-09-13 | Compositions and methods for treating collagen-mediated diseases |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL192878A IL192878A (en) | 2006-01-30 | 2008-07-17 | Clostridium histolyticum collagenase i and collagenase ii, drug comprising the same and process for producing said drug |
| IL245434A IL245434A (en) | 2006-01-30 | 2016-05-02 | Collagen-mediated Diseases and Methods for the Treatment of Collagen |
| IL254184A IL254184B (en) | 2006-01-30 | 2017-08-28 | Compositions and methods for treating collagen-mediated diseases |
| IL264361A IL264361B (en) | 2006-01-30 | 2019-01-21 | Compositions and methods for treating collagen-mediated diseases |
| IL277322A IL277322B (en) | 2006-01-30 | 2020-09-13 | Compositions and methods for treating collagen-mediated diseases |
Country Status (17)
| Country | Link |
|---|---|
| US (16) | US7811560B2 (enExample) |
| EP (6) | EP2474321B1 (enExample) |
| JP (8) | JP5309289B2 (enExample) |
| KR (2) | KR20110046537A (enExample) |
| CN (2) | CN101400788B (enExample) |
| AU (2) | AU2007211313C1 (enExample) |
| BR (1) | BRPI0708017A2 (enExample) |
| CA (1) | CA2637262C (enExample) |
| DK (2) | DK2474321T3 (enExample) |
| ES (3) | ES2729941T3 (enExample) |
| HU (2) | HUE044220T2 (enExample) |
| IL (6) | IL291175B2 (enExample) |
| MX (1) | MX2008009756A (enExample) |
| NZ (2) | NZ569882A (enExample) |
| PT (2) | PT1987141T (enExample) |
| TR (1) | TR201903008T4 (enExample) |
| WO (1) | WO2007089851A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6958150B2 (en) | 1994-12-15 | 2005-10-25 | Advance Biofactures Of Curacao, N.V. | Reduction of adipose tissue |
| US20070224184A1 (en) * | 2006-02-22 | 2007-09-27 | The Research Foundation Of The State University Of New York | Method for treating cellulite |
| US7811560B2 (en) * | 2006-01-30 | 2010-10-12 | Auxilium Us Holdings, Llc | Compositions and methods for treating collagen-mediated diseases |
| US10071143B1 (en) | 2007-05-03 | 2018-09-11 | The Research Foundation For The State University Of New York | Methods for non-surgical treatment of carpal tunnel syndrome |
| EP2725035A1 (en) | 2007-10-02 | 2014-04-30 | Avaxia Biologics, Inc. | Antibody therapy for use in the digestive tract |
| US20100159564A1 (en) * | 2007-11-30 | 2010-06-24 | Dwulet Francis E | Protease resistant recombinant bacterial collagenases |
| TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
| EP2130551B1 (en) | 2008-06-02 | 2012-06-06 | Roche Diagnostics GmbH | Improved purification of collagenases from clostridium histolyticum liquid culture |
| US8236356B2 (en) | 2008-06-11 | 2012-08-07 | Roche Diagnostics Operations, Inc. | Growth medium for Clostridium histolyticum |
| WO2010102262A1 (en) | 2009-03-06 | 2010-09-10 | Halozyme, Inc. | Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof |
| ES2385239B1 (es) | 2010-09-30 | 2013-06-19 | Proteos Biotech S.L.U. | Uso de colagenasa g recombinante, colagenasa h recombinante y pz-peptidasa recombinante para el tratamiento de enfermedades que cursan con alteraciones del colágeno. |
| WO2012125948A1 (en) | 2011-03-16 | 2012-09-20 | Biospecifics Technologies Corp. | Compositions and methods for producing clostridial collagenases |
| MX350145B (es) | 2011-07-20 | 2017-08-28 | Mediwound Ltd | Extracto proteolitico a partir de bromelaina para el tratamiento de trastornos del tejido conectivo. |
| WO2013059619A1 (en) * | 2011-10-21 | 2013-04-25 | Auxilium Pharmaceuticals, Inc. | Method of treating or reducing efp |
| EP4015627B1 (en) | 2012-01-12 | 2023-09-27 | Endo Global Ventures | Clostridium histolyticum enzyme |
| ITPD20120118A1 (it) | 2012-04-18 | 2013-10-19 | Fidia Farmaceutici | "nuovo processo di produzione e purificazione dell'enzima collagenasi da vibrio alginolyticus" |
| JP2015521169A (ja) | 2012-05-01 | 2015-07-27 | プロテオリース リミテッド | 抜歯する方法 |
| BR102012013110A2 (pt) | 2012-05-31 | 2014-05-27 | Cristalia Prod Quimicos Farm | Meio de cultura para bactérias do gênero clostridium livre de componentes de origem animal e processo para produção de sobrenadante contendo uma ou mais proteases com atividade colagenolítica e gelatinolítica |
| US9636385B2 (en) | 2012-10-24 | 2017-05-02 | The Research Foundation For The State University Of New York | Use of collagenase to treat glaucoma |
| US20150196625A9 (en) | 2013-01-07 | 2015-07-16 | Rudolph D. Paladini | Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof |
| EP3834840B8 (en) | 2013-03-15 | 2025-09-17 | Endo Biologics Limited | Treatment method and product for uterine fibroids using purified collagenase |
| US20160000890A1 (en) * | 2013-03-15 | 2016-01-07 | Biospecifics Technologies Corp. | Thermosensitive hydrogel collagenase formulations |
| CA2915814A1 (en) * | 2013-06-18 | 2014-12-24 | Imprimis Pharmaceuticals Inc. | Local use of pentoxifylline to treat peyronie's disease |
| US10383875B2 (en) | 2013-06-18 | 2019-08-20 | Harrow Ip, Llc | Pharmaceutical formulations of xanthine or xanthine derivatives, and their use |
| US10117892B2 (en) * | 2013-08-29 | 2018-11-06 | Allergan, Inc. | Devices and methods for reducing the appearance of cellulite |
| CN103751102A (zh) | 2014-01-15 | 2014-04-30 | 上海交通大学 | 一种胶原酶温敏水凝胶及其制备方法和应用 |
| CN105477627B (zh) * | 2014-09-19 | 2021-04-30 | 山东蓝金生物工程有限公司 | 治疗前列腺癌的组合物及其用途 |
| CN105412917B (zh) * | 2014-09-19 | 2021-04-30 | 达森生物药业有限公司 | 治疗实体瘤的抗癌组合物及其用途 |
| CN105412916B (zh) * | 2014-09-19 | 2021-04-30 | 达森生物药业有限公司 | 治疗乳腺癌的组合物及其用途 |
| CN105477628B (zh) * | 2014-09-19 | 2021-04-30 | 山东蓝金生物工程有限公司 | 抗癌组合物及其用途 |
| DE202014105440U1 (de) * | 2014-11-12 | 2016-02-15 | Bilz Werkzeugfabrik Gmbh & Co. Kg | Werkzeugaufnahme |
| KR101723168B1 (ko) | 2015-04-28 | 2017-04-05 | 주식회사 대웅 | 보툴리눔 독소의 제조를 위한 배지 조성물 |
| US10303245B2 (en) * | 2015-05-04 | 2019-05-28 | Adobe Inc. | Methods and devices for detecting and responding to changes in eye conditions during presentation of video on electronic devices |
| KR20230003601A (ko) | 2017-03-01 | 2023-01-06 | 엔도 벤쳐즈 리미티드 | 셀룰라이트를 평가하고 치료하기 위한 장치 및 방법 |
| KR20240001279A (ko) | 2017-03-28 | 2024-01-03 | 엔도 벤쳐즈 리미티드 | 개선된 콜라게나제 생성 방법 |
| WO2020021332A2 (en) | 2018-07-12 | 2020-01-30 | Endo Global Aesthetics Limited | Injection techniques for the treatment of cellulite |
| WO2020021330A2 (en) | 2018-07-12 | 2020-01-30 | Endo Global Aesthetics Limited | Injection techniques for the treatment of cellulite |
| JP7628492B2 (ja) | 2018-09-18 | 2025-02-10 | エンド グローバル エステティックス リミテッド | セルライトを治療するための組成物および方法 |
| MX2021008017A (es) | 2019-01-06 | 2021-08-05 | Endo Global Aesthetics Ltd | Formulaciones de colagenasa y metodos de produccion de las mismas. |
| CA3157517A1 (en) | 2019-10-15 | 2021-04-22 | The Johns Hopkins University | Treatment of uterine fibroids using purified collagenase |
| WO2023131588A1 (en) | 2022-01-05 | 2023-07-13 | Nordmark Pharma Gmbh | Culture medium for cultivating hathewaya histolytica (or clostridium histolyticum) and the production of one or more proteases |
| CN116102638B (zh) * | 2023-01-09 | 2025-05-16 | 中国农业科学院农产品加工研究所 | 基于亲和吸附富集骨胶原蛋白成骨活性肽的方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61289885A (ja) * | 1985-06-14 | 1986-12-19 | Nitta Zerachin Kk | コラゲナ−ゼおよびコラゲナ−ゼの製造方法 |
| JP2898022B2 (ja) * | 1989-09-05 | 1999-05-31 | 株式会社ニッピ | コラーゲン分解酵素の製造方法 |
| CA2047306A1 (en) * | 1990-07-23 | 1992-01-24 | Milan Holjevac | Mutant bacterium clostridium histolyticum, a process for the obtaining thereof, and its use in the production of clostripain-free collagenase |
| US5393792A (en) * | 1991-11-20 | 1995-02-28 | Advance Biofactures Of Curacao, N.V. | High dosage topical forms of collagenase |
| US5462739A (en) * | 1991-11-21 | 1995-10-31 | Yeda Research And Development Co., Ltd. | Microdelivery device and method for enhanced drug administration to the eye |
| CA2138948A1 (en) * | 1992-06-22 | 1994-01-06 | Hun-Chi Lin | Molecular cloning of the genes responsible for collagenase production from clostridium histolyticum |
| JP3186881B2 (ja) * | 1993-02-18 | 2001-07-11 | 倉敷紡績株式会社 | 肝細胞の分離方法 |
| US5332503A (en) * | 1993-04-16 | 1994-07-26 | Baxter International Inc. | Process for purifying collagenase |
| CA2189646C (en) * | 1994-06-24 | 1999-05-25 | Francis E. Dwulet | A purified mixture of collagenases and two other proteases obtained from clostridium histolyticum |
| US5589171A (en) | 1994-08-22 | 1996-12-31 | Advance Biofactures Of Curacao | Treatment of Dupuytren's disease with collagenase |
| CZ280397A3 (cs) * | 1995-03-16 | 1998-04-15 | Knoll Aktiengesellschaft | Nové, definované směsi enzymů pro získávání buněk a pro léčbu poranění |
| US5989888A (en) * | 1996-01-24 | 1999-11-23 | Roche Diagnostics Corporation | Purified mixture of collagenase I, collagenase II and two other proteases |
| ATE272109T1 (de) * | 1996-11-19 | 2004-08-15 | Roche Diagnostics Gmbh | Rekombinante collagenase typ i aus clostridium histolyticum und ihre verwendung zur isolierung von zellen und zellverbänden |
| US5830741A (en) * | 1996-12-06 | 1998-11-03 | Boehringer Mannheim Corporation | Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease |
| US6086872A (en) | 1997-03-27 | 2000-07-11 | Advance Biofactures Of Curacao, Nv | Amelioration of dupuytren's disease |
| JPH10262658A (ja) * | 1997-03-28 | 1998-10-06 | Kikkoman Corp | ザルコシン・オキシダーゼの結晶、その製造方法及び三次元構造 |
| US6022539A (en) | 1999-06-03 | 2000-02-08 | Advance Biofactures Of Curacao | Amelioration of peyronie's disease |
| CN1308442C (zh) * | 2001-07-02 | 2007-04-04 | 诺尔玛克药物有限责任及股份两合公司 | 纯化酶的方法和按此产生出的经纯化的酶以及该酶的用途 |
| EP1462519A1 (en) * | 2003-03-24 | 2004-09-29 | Boehringer Ingelheim Austria GmbH | Method and devices for producing biomolecules |
| JP4205496B2 (ja) * | 2003-06-19 | 2009-01-07 | 三菱化学株式会社 | 新規カルボニル還元酵素及びこれをコードするｄｎａ、ならびにこれらを利用した光学活性アルコールの製造方法 |
| NZ548871A (en) * | 2004-01-30 | 2009-06-26 | Shire Pharmaceuticals Ireland | Use of arylsulfatase A for treating metachromatic leukodystrophy |
| US7355027B2 (en) * | 2004-06-16 | 2008-04-08 | Dynport Vaccine Company Llc | Bacillus anthracis protective antigen |
| EP1781697B1 (en) * | 2004-07-07 | 2009-04-22 | H.Lundbeck A/S | Novel carbamylated epo and method for its production |
| JP2008505928A (ja) * | 2004-07-08 | 2008-02-28 | アムジェン インコーポレーテッド | 治療用ペプチド |
| ES2548516T3 (es) * | 2005-01-21 | 2015-10-19 | The Research Foundation Of The State University Of New York | Métodos para el tratamiento de la capsulitis adhesiva |
| US7811560B2 (en) * | 2006-01-30 | 2010-10-12 | Auxilium Us Holdings, Llc | Compositions and methods for treating collagen-mediated diseases |
-
2007
- 2007-01-29 US US11/699,302 patent/US7811560B2/en active Active
- 2007-01-30 TR TR2019/03008T patent/TR201903008T4/tr unknown
- 2007-01-30 JP JP2008552504A patent/JP5309289B2/ja active Active
- 2007-01-30 ES ES12155233T patent/ES2729941T3/es active Active
- 2007-01-30 EP EP12155233.5A patent/EP2474321B1/en active Active
- 2007-01-30 ES ES07762860T patent/ES2709202T3/es active Active
- 2007-01-30 EP EP12155228A patent/EP2474319A1/en not_active Withdrawn
- 2007-01-30 BR BRPI0708017-4A patent/BRPI0708017A2/pt not_active Application Discontinuation
- 2007-01-30 KR KR1020117006197A patent/KR20110046537A/ko not_active Ceased
- 2007-01-30 EP EP18209918.4A patent/EP3508571B1/en active Active
- 2007-01-30 IL IL291175A patent/IL291175B2/en unknown
- 2007-01-30 NZ NZ569882A patent/NZ569882A/en unknown
- 2007-01-30 HU HUE12155233 patent/HUE044220T2/hu unknown
- 2007-01-30 KR KR1020087021302A patent/KR20080093142A/ko not_active Ceased
- 2007-01-30 NZ NZ593907A patent/NZ593907A/xx unknown
- 2007-01-30 EP EP07762860.0A patent/EP1987141B8/en active Active
- 2007-01-30 DK DK12155233.5T patent/DK2474321T3/da active
- 2007-01-30 ES ES18209918T patent/ES2992881T3/es active Active
- 2007-01-30 PT PT07762860T patent/PT1987141T/pt unknown
- 2007-01-30 PT PT12155233T patent/PT2474321T/pt unknown
- 2007-01-30 EP EP12155230A patent/EP2474320A1/en not_active Withdrawn
- 2007-01-30 AU AU2007211313A patent/AU2007211313C1/en active Active
- 2007-01-30 CN CN200780008746.5A patent/CN101400788B/zh active Active
- 2007-01-30 HU HUE07762860A patent/HUE041764T2/hu unknown
- 2007-01-30 MX MX2008009756A patent/MX2008009756A/es active IP Right Grant
- 2007-01-30 DK DK07762860.0T patent/DK1987141T3/en active
- 2007-01-30 CN CN201610369324.1A patent/CN105999244B/zh active Active
- 2007-01-30 WO PCT/US2007/002654 patent/WO2007089851A2/en not_active Ceased
- 2007-01-30 EP EP24194815.7A patent/EP4483952A3/en active Pending
- 2007-01-30 CA CA2637262A patent/CA2637262C/en active Active
-
2008
- 2008-07-17 IL IL192878A patent/IL192878A/en active IP Right Grant
-
2010
- 2010-04-13 US US12/759,065 patent/US20100233151A1/en not_active Abandoned
- 2010-07-16 US US12/837,933 patent/US20100330065A1/en not_active Abandoned
- 2010-08-30 US US12/871,159 patent/US20110158972A1/en not_active Abandoned
-
2011
- 2011-04-12 US US13/084,735 patent/US20110243920A1/en not_active Abandoned
- 2011-04-12 US US13/084,716 patent/US20110189153A1/en not_active Abandoned
- 2011-04-12 US US13/084,719 patent/US20110189163A1/en not_active Abandoned
- 2011-04-12 US US13/084,734 patent/US20110243909A1/en not_active Abandoned
- 2011-04-12 US US13/084,722 patent/US20110243908A1/en not_active Abandoned
- 2011-04-12 US US13/084,720 patent/US20110243919A1/en not_active Abandoned
- 2011-12-27 JP JP2011285435A patent/JP2012070758A/ja not_active Withdrawn
-
2012
- 2012-02-15 AU AU2012200863A patent/AU2012200863B2/en active Active
- 2012-12-13 US US13/713,019 patent/US20140004094A1/en not_active Abandoned
-
2015
- 2015-02-04 US US14/613,882 patent/US20160000889A1/en not_active Abandoned
- 2015-03-31 JP JP2015072261A patent/JP6230200B2/ja active Active
-
2016
- 2016-05-02 IL IL245434A patent/IL245434A/en active IP Right Grant
- 2016-05-20 US US15/160,392 patent/US20170087229A1/en not_active Abandoned
- 2016-10-04 JP JP2016196519A patent/JP6389493B2/ja active Active
-
2017
- 2017-08-28 IL IL254184A patent/IL254184B/en active IP Right Grant
- 2017-09-08 JP JP2017173236A patent/JP6851943B2/ja active Active
-
2018
- 2018-07-03 JP JP2018126943A patent/JP6792596B2/ja active Active
-
2019
- 2019-01-21 IL IL264361A patent/IL264361B/en active IP Right Grant
- 2019-12-19 JP JP2019229674A patent/JP6944989B2/ja active Active
-
2020
- 2020-09-13 IL IL277322A patent/IL277322B/en unknown
- 2020-10-02 US US17/062,372 patent/US20210106659A1/en not_active Abandoned
-
2021
- 2021-04-19 JP JP2021070232A patent/JP7191152B2/ja active Active
-
2022
- 2022-09-14 US US17/932,230 patent/US20230158127A1/en not_active Abandoned
-
2024
- 2024-05-13 US US18/662,818 patent/US20240299508A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291175B2 (en) | Compositions and methods for treating collagen-mediated diseases | |
| AU2022203288B2 (en) | Antimicrobial therapy | |
| EP3821904B1 (en) | Formula of neuregulin preparation | |
| JP2016505539A5 (enExample) | ||
| JP6928324B1 (ja) | 滑膜細胞増殖抑制剤、関節腔注入剤、及び食品組成物 | |
| CN101970459A (zh) | 抗微生物化合物 | |
| CA2332817A1 (en) | Il-6 antagonist peptides | |
| KR20160140137A (ko) | 결핵균 독소-항독소 체계를 표적으로 하는 항생 펩타이드 및 이의 용도 | |
| JP2012512633A5 (enExample) | ||
| CN108314727B (zh) | 膜型金属蛋白酶抑制蛋白及其用途 | |
| JP2006505290A5 (enExample) | ||
| US10336788B2 (en) | Inhibition of cardiac fibrosis in myocardial infarction | |
| RU2715694C1 (ru) | Фармацевтическая композиция для лечения глазных инфекций, вызванных метициллин-устойчивыми штаммами Staphylococcus aureus, включающая в качестве активного начала N-концевой CHAP-домен эндолизина бактериофага K Staphylococcus aureus | |
| KR100840804B1 (ko) | 이종 올리고리보누클레오티드 및/또는폴리리보누클레오티드를 함유하는 약제 | |
| KR20250007434A (ko) | 단백질의 뭉침을 저해하고 활성을 보호해주는 펩타이드 | |
| CN116983391A (zh) | 一种增强免疫力和防治感染性疾病及其并发症的治疗方法 | |
| HK40089238A (zh) | 抗微生物疗法 | |
| CN117562913A (zh) | 连翘活性成分组合在制备拮抗SARS-CoV-2突变毒株的药物中的应用 | |
| Kapetanaki et al. | Aging Mesenchymal Stem Cells in Lung Disease | |
| EP2110384A1 (en) | Hepatopoietin and use thereof | |
| WO2013066795A1 (en) | Stable pharmaceutical formulations of growth factor peptides | |
| CN101642463A (zh) | 一种肿瘤抑制剂nrn1sr4 | |
| CN101643729A (zh) | 核酸分子nrn1sr22及其在制备抗癌药物中的应用 | |
| KR20140022701A (ko) | 약물 전달체인 텔로머라제 펩티드를 포함하는 조성물 | |
| CN101007835A (zh) | 核酸分子rtn4bsr5及其在制备抗癌药物中的应用 |